According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “
Several other analysts have also commented on NXTC. Morgan Stanley increased their price objective on NextCure from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Piper Jaffray Companies reiterated a “positive” rating and set a $95.00 price objective (up previously from $54.00) on shares of NextCure in a report on Monday. Finally, Bank of America upped their target price on NextCure from $27.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, September 9th.
NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, research analysts forecast that NextCure will post -1.8 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Victory Capital Management Inc. acquired a new position in shares of NextCure in the 2nd quarter valued at $48,000. Tower Research Capital LLC TRC acquired a new position in shares of NextCure in the 2nd quarter valued at $96,000. Morgan Stanley acquired a new position in shares of NextCure in the 2nd quarter valued at $101,000. Strs Ohio increased its position in shares of NextCure by 625.0% in the 3rd quarter. Strs Ohio now owns 5,800 shares of the company’s stock valued at $178,000 after acquiring an additional 5,000 shares during the period. Finally, Northern Trust Corp acquired a new stake in NextCure during the 2nd quarter worth about $337,000. 47.19% of the stock is currently owned by hedge funds and other institutional investors.
NextCure Company Profile
There is no company description available for NextCure Inc
Recommended Story: Percentage Decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.